Macromoltek

We design antibodies computationally for difficult targets

Founded 20103 employees

DesignArtificial intelligence and machine learningDeep TechBiotechDrug Discovery

About

We design antibodies computationally for difficult targets

Recent press

Macromoltek Announces Computational De Novo Antibody Design Offering, Targeting COVID-19
www.prnewswire.com
/PRNewswire/ -- Macromoltek, Inc. today announced computational de novo design capability to speed up the development of human monoclonal antibodies for the...
Macromoltek Deploys Computational Design Platform To Enable Cytovia Therapeutics Drug Development For COVID-19
www.prnewswire.com
/PRNewswire/ -- Macromoltek, Inc. today announced the application of its computational design technology for their recently disclosed partnership with Cytovia...

See something off about this company?